Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Viroimmunotherapy for ColorectalCancer: Â Clinical Studies 28536354 2018 11 13 2227-9059 5 1 2017 Mar 10 Biomedicines Biomedicines Viroimmunotherapy for ColorectalCancer: Clinical Studies. E11 10.3390/biomedicines5010011 Colorectalcancer is a leading cause of cancer incidence and death. Therapies for those with unresectable or recurrent disease are not considered curative at present. More effective and less toxic therapies are desperately needed. Historically, the immune system was thought (...) the highest likelihood of viral efficacy. This article reviews the variety of mechanisms explored for viruses such as immunotherapy for colorectalcancer. Chaurasiya Shyambabu S Beckman Research Institute, City of Hope National Medical Center, Duarte 91010, CA, USA. firstname.lastname@example.org. Warner Susanne S Beckman Research Institute, City of Hope National Medical Center, Duarte 91010, CA, USA. email@example.com. eng Journal Article Review 2017 03 10 Switzerland Biomedicines 101691304 2227-9059 colorectal
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastaticcolorectalcancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study 28761727 2018 11 13 2059-7029 2 1 2017 ESMO open ESMO Open S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastaticcolorectalcancer: updated overall survival analyses (...) of the open-label, non-inferiority, randomised phase III: SOFT study. e000135 10.1136/esmoopen-2016-000135 The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l -leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastaticcolorectalcancer (mCRC). The overall survival (OS) data were immature at the time of the primary analysis
Exploration of small RNA-seq data for small non-coding RNAs in Human ColorectalCancer 28348640 2018 11 13 1839-9940 5 2017 Journal of genomics J Genomics Exploration of small RNA-seq data for small non-coding RNAs in Human ColorectalCancer. 16-31 10.7150/jgen.18856 Background: Improved healthcare and recent breakthroughs in technology have substantially reduced cancer mortality rates worldwide. Recent advancements in next-generation sequencing (NGS) have allowed genomic analysis of the human (...) available small RNA sequencing data from colorectal tissue samples of eight matched patients (benign, tumor, and metastasis) and remapped the data for various small RNA annotations. We identified aberrant expression of 13 miRNAs in tumor and metastasis specimens [tumor vs benign group (19 miRNAs) and metastasis vs benign group (38 miRNAs)] of which five were upregulated, and eight were downregulated, during disease progression. Pathway analysis of aberrantly expressed miRNAs showed that the majority
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastaticcolorectalcancer in the CAPRI-GOIM first-line trial 28848656 2018 11 13 2059-7029 1 6 2016 ESMO open ESMO Open Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastaticcolorectalcancer in the CAPRI-GOIM first-line trial. e000086 10.1136/esmoopen-2016-000086 In the cetuximab after progression in KRAS wild-type colorectalcancer patients (CAPRI) trial patients (...) with metastaticcolorectalcancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin (FOLFOX) with or without cetuximab until progression. Limited data are available on the efficacy and safety of anti-epidermal growth factor receptor (anti-EGFR) agents on elderly patients with mCRC. In the current study we evaluated the efficacy and safety of FOLFIRI plus cetuximab in age-defined subgroups. A post-hoc analysis
Post-colonoscopy colorectalcancer: the key role of molecular pathological epidemiology 28275741 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Post-colonoscopy colorectalcancer: the key role of molecular pathological epidemiology. 9 10.21037/tgh.2017.01.05 Hamada Tsuyoshi T Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Nishihara Reiko R Department of Medical Oncology, Dana-Farber (...) Cancer Institute, Harvard Medical School, Boston, MA, USA; ; Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA;; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Ogino Shuji S Department
Pattern and Dynamics of Distant Metastases in MetastaticColorectalCancer 28612020 2018 11 13 2297-4725 33 1 2017 Mar Visceral medicine Visc Med Pattern and Dynamics of Distant Metastases in MetastaticColorectalCancer. 70-75 10.1159/000454687 Few studies report the incidence of metastatic patterns in colorectalcancer. Furthermore, little is known about dynamic aspects of these metastases during the course of disease. This retrospective cohort study involved 385 patients who received anti (...) -tumor treatment at our institution (Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-University Munich, Germany) for metastaticcolorectal adenocarcinoma between 2007 and 2014. We reviewed all available imaging results of these patients to document the presence and detailed localization of metastases. Most of the evaluated patients were initially diagnosed with metastases in the liver (70%), followed by the lungs (24%), distant lymph nodes (16%), and peritoneum (15
Oligometastatic Disease in ColorectalCancer â€“ How to Proceed? 28612013 2018 11 13 2297-4725 33 1 2017 Mar Visceral medicine Visc Med Oligometastatic Disease in ColorectalCancer - How to Proceed? 23-28 10.1159/000454688 Oligometastatic disease in colorectalcancer may affect the liver, lung, and peritoneum. This review mainly focuses on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic strategies drawn from the current literature and consensus conferences (...) Lancet Oncol. 2016 Oct;17 (10 ):1426-1434 27575024 Cancer Treat Rev. 2015 Nov;41(9):729-41 26417845 Lancet Oncol. 2010 Jan;11(1):38-47 19942479 Br J Surg. 2013 Oct;100(11):1414-20 24037559 Ann Surg. 2008 Jan;247(1):125-35 18156932 World J Surg. 2007 Mar;31(3):511-21 17308854 J Gastrointest Surg. 2010 Nov;14 (11):1691-700 20839072 Ann Surg. 2016 May;263(5):e73 26720433 Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9 25190710 J Gastrointest Surg. 2012 Apr;16(4):806-14 22258869 Ann Surg. 2012 Mar;255(3):534-9
Thermal Ablation in the Management of ColorectalCancer Patients with Oligometastatic Liver Disease 28612019 2018 11 13 2297-4725 33 1 2017 Mar Visceral medicine Visc Med Thermal Ablation in the Management of ColorectalCancer Patients with Oligometastatic Liver Disease. 62-68 10.1159/000454697 Surgical resection of limited colorectal liver disease improves long-term survival and can be curative in a subset of selected cases. Image-guided percutaneous ablation therapies have emerged as safe (...) and effective alternative options for selected patients with unresectable colorectal liver metastases (CLM) that can be ablated with margins. Ablation causes focal destruction of tissue and has increasingly been shown to provide durable eradication of tumors. A selective review of literature was conducted in PubMed, focusing on recent studies reporting on the safety, efficacy, and long-term outcomes of percutaneous ablation modalities in the treatment of CLM. The present work gives an overview
Tumor Deposits in ColorectalCancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis 28029327 2016 12 28 2017 04 03 1527-7755 35 10 2017 Apr 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Tumor Deposits in ColorectalCancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis. 1119-1127 10.1200/JCO.2016.68.9091 Purpose Colorectalcancer (CRC) treatment is largely determined (...) by tumor stage. Despite improvements made in the treatment of various types of metastatic disease, staging has not been refined. The role of tumor deposits (TDs) in staging remains debated. We have assessed the relation of TDs with metastatic pattern to evaluate whether TDs might add significant new information to staging. Methods We performed a systematic literature search that was focused on the role of TDs in CRC. Studies with neoadjuvant-treated patients were excluded. Data on stage, histologic
[Trifluridine/tipiracil (colorectalcancer) - benefit assessment according to õ35a Social Code Book V] Trifluridin/tipiracil (kolorektalkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-54 [Trifluridine/tipiracil (colorectalcancer) - benefit assessment according to §35a Social Code Book V] Trifluridin/tipiracil (kolorektalkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-54 [Trifluridine/tipiracil (colorectalcancer) - benefit assessment (...) . [Trifluridine/tipiracil (colorectalcancer) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 461. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Combined Chemotherapy Protocols; ColorectalNeoplasms; Germany; Humans; State Medicine; Trifluridine Language Published German Country of organisation Germany English summary There is no English language
Colorectalcancer. Every year, more than 945000 people develop colorectalcancer worldwide, and around 492000 patients die. This form of cancer develops sporadically, in the setting of hereditary cancer syndromes, or on the basis of inflammatory bowel diseases. Screening and prevention programmes are available for all these causes and should be more widely publicised. The adenoma-carcinoma sequence is the basis for development of colorectalcancer, and the underlying molecular changes have (...) largely been identified. Prognosis depends on factors related to the patient, treatment, and tumour, and the expertise of the treatment team is one of the major determinants of outcome. New information on the molecular basis of this cancer have led to the development of targeted therapeutic options, which are being tested in clinical trials. Further clinical progress will largely depend on the broader implementation of multidisciplinary treatment strategies following the principles of evidence-based medicine.
Colorectalcancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on ColorectalCancer GIE SPECIAL ARTICLE Colorectalcancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on ColorectalCancer Douglas K. Rex, MD, 1 C. Richard Boland, MD, 2 Jason A. Dominitz, MD, MHS, 3 Francis M. Giardiello, MD, 4 David A. Johnson, MD, 5 Tonya Kaltenbach, MD, 6 Theodore R. Levin, MD, 7 David Lieberman, MD, 8 Douglas J (...) . Robertson, MD, MPH 9 Indianapolis, Indiana; Seattle, Washington; Baltimore, Maryland; Norfolk, Virginia; San Diego, San Francisco, Walnut Creek, California; Portland, Oregon; White River Junction, Vermont, USA This document updates the colorectalcancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of ColorectalCancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Soci- ety for Gastrointestinal
Recommendations on fecal immunochemical testing to screen for colorectalneoplasia: a consensus statement by the US Multi-Society Task Force on colorectalcancer GIE SPECIAL ARTICLE Recommendations on fecal immunochemical testing to screen for colorectalneoplasia: a consensus statement by the US Multi-Society Task Force on colorectalcancer Douglas J. Robertson, 1,2, * Jeffrey K. Lee, 3, * C. Richard Boland, 4 Jason A. Dominitz, 5 Francis M. Giardiello, 6 David A. Johnson, 7 Tonya Kaltenbach (...) has a num- ber of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summa- rizes current evidence for FIT in colorectalneoplasia detection and the comparative effectiveness of FIT rela- tive to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT applica- tion were developed and quality metrics for program im- plementation proposed. Stool testing for occult blood has long been recommen- ded for colorectal